Brown, Lisle/Cummings’s ARK Genomic Revolution ETF ARKG Stock Holding History

Brown, Lisle/Cummings’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1K	Buy	526 +201	+62%	+$6.4K	0.01%	492
2026 Q1	$8.59K	Hold	325	–	–	﹤0.01%	600
2025 Q4	$9.41K	Hold	325	–	–	﹤0.01%	506
2025 Q3	$9.03K	Hold	325	–	–	﹤0.01%	515
2025 Q2	$7.91K	Hold	325	–	–	﹤0.01%	525
2025 Q1	$6.75K	Sell	325 -75	-19%	-$1.88K	﹤0.01%	532
2024 Q4	$9.42K	Buy	400 +21	+6%	+$517	﹤0.01%	489
2024 Q3	$9.7K	Hold	379	–	–	﹤0.01%	470
2024 Q2	$8.9K	Buy	379 +129	+52%	+$3.26K	﹤0.01%	466
2024 Q1	$7.19K	Hold	250	–	–	﹤0.01%	461
2023 Q4	$8.2K	Hold	250	–	–	﹤0.01%	458
2023 Q3	$6.96K	Hold	250	–	–	﹤0.01%	444
2023 Q2	$8.52K	Hold	250	–	–	﹤0.01%	432
2023 Q1	$7.52K	Buy	250 +75	+43%	+$2.32K	﹤0.01%	428
2022 Q4	$4.94K	Buy	175 +75	+75%	+$2.38K	﹤0.01%	442
2022 Q3	$3.29K	Hold	100	–	–	﹤0.01%	450
2022 Q2	$3.15K	Hold	100	–	–	﹤0.01%	433
2022 Q1	$4.59K	Buy	+100	New	+$4.77K	﹤0.01%	433

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Brown, Lisle/Cummings's ARKG Position: Q2 2026 in Review

Brown, Lisle/Cummings increased its ARK Genomic Revolution ETF (ARKG) stake by 62% in Q2 2026, buying an estimated $6.4K and bringing the position to 526 shares worth $22.1K. The position accounts for 0.01% of the portfolio, ranked #492.

Brown, Lisle/Cummings first reported a position in ARKG in Q1 2022 and has held it in 18 quarters since. 274 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Brown, Lisle/Cummings held 526 shares of ARK Genomic Revolution ETF worth $22.1K as of Q2 2026.
Brown, Lisle/Cummings bought 201 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $6.4K.
ARK Genomic Revolution ETF made up 0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #492 holding.
Brown, Lisle/Cummings first reported a position in ARK Genomic Revolution ETF in Q1 2022 and has held it in 18 quarters since.
274 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.